###begin article-title 0
Sec61p Is Required for ERAD-L
###end article-title 0
###begin p 1
###xml 76 107 76 107 <email xmlns:xlink="http://www.w3.org/1999/xlink">colin.stirling@manchester.ac.uk</email>
 To whom correspondence should be addressed. Tel.: 44-161-275-5104; E-mail: colin.stirling@manchester.ac.uk. 
###end p 1
###begin p 2
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice
###end p 2
###begin p 3
 applies to Author Choice Articles
###end p 3
###begin p 4
Misfolded proteins in the endoplasmic reticulum (ER) are exported to the cytosol for degradation by the proteasome in a process known as ER-associated degradation (ERAD). CPY* is a well characterized ERAD substrate whose degradation is dependent upon the Hrd1 complex. However, although the functions of some of the components of this complex are known, the nature of the protein dislocation channel remains obscure. Sec61p has been suggested as an obvious candidate because of its role as a protein-conducting channel through which polypeptides are initially translocated into the ER. However, it has not yet been possible to functionally dissect any role for Sec61p in dislocation from its essential function in translocation. By changing the translocation properties of a series of novel ERAD substrates, we are able to separate these two events and find that functional Sec61p is essential for the ERAD-L pathway.
###end p 4
###begin p 5
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Author's Choice</italic>
Author's Choice-Final version full access.
###end p 5
###begin p 6
###xml 27 41 27 41 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink">Wellcome Trust</grant-sponsor>
###xml 48 54 48 54 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink">074149</grant-num>
###xml 197 210 197 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">advertisement</italic>
This work was supported by Wellcome Trust Grant 074149. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 6
###begin p 7
The on-line version of this article (available at ) contains supplemental Fig. 1.
###end p 7
###begin p 8
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fn" rid="fn3">2</xref>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
Perturbations in protein biogenesis in the ER2 can lead to the accumulation of misfolded proteins with potentially catastrophic cytotoxic consequences. The ERAD quality control system identifies aberrant proteins and targets them for destruction. This disposal mechanism involves misfolded proteins being "dislocated" across the ER membrane to the cytosol where they are ubiquitinated before being delivered to the proteasome for degradation (1).
###end p 8
###begin p 9
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref3">3</xref>
###xml 865 866 865 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref4">4</xref>
###xml 1231 1232 1231 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref1">1</xref>
Three distinct ERAD pathways can be distinguished according to the topology of the misfolded lesion. ER lumenal proteins are degraded via the ERAD-L pathway, as are integral membrane proteins with lesions in a lumenal domain. Membrane proteins with cytosolic lesions are degraded by the ERAD-C pathway (2), whereas those with misfolded transmembrane domains are degraded by the ERAD-M pathway (3, 4). All three pathways require the cytosolic Cdc48p-Ufd1p-Npl4p complex, which delivers ubiquitinated substrates to the proteasome. ERAD-L involves recognition of aberrant domains by a lumenal surveillance complex, comprising Yos9p and Kar2p, which maintains the substrate in an ERAD-competent conformation. The substrate is then delivered to the membrane-associated Hrd1 complex comprising the E3 ubiquitin ligase Hrd1p and its co-factors Hrd3p, Usa1p, and Der1p (3, 4). At this stage the substrate must be dislocated across the ER membrane where it is ubiquitinated by the Hrd1p ubiquitin ligase in combination with the E2 ubiquitin-conjugating enzyme Ubc7p and its membrane anchor, Cue1p. The ubiquitinated substrate is then passed to the Cdc48p-Ufd1p-Npl4p complex, which is itself anchored to the membrane by the Ubx2p receptor (1).
###end p 9
###begin p 10
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref5">5</xref>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref6">6</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 144 149 <span type="species:ncbi:4932">yeast</span>
###xml 285 290 <span type="species:ncbi:4932">Yeast</span>
###xml 482 487 <span type="species:ncbi:4932">yeast</span>
The identity of the protein dislocation channel has been the subject of considerable debate. Derlin-1, a recently identified human homologue of yeast Der1p has been suggested to form a pore in the ER membrane through which unfolded ERAD substrates are exported for degradation (5, 6). Yeast Der1p is an integral membrane protein required for the degradation of ERAD-L substrates including CPY*, KHN, and KWW (2, 7), but the molecular function of Der1p/Derlin-1 is not yet known. In yeast, Der1p is not essential for viability, but its widespread conservation does suggest an important role in eukaryotes.
###end p 10
###begin p 11
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref8">8</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref9">9</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref11">11</xref>
###xml 377 384 377 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 389 397 389 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref12">12</xref>
###xml 558 563 558 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61</italic>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref13">13</xref>
###xml 631 638 631 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-2</italic>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref14">14</xref>
###xml 736 741 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61</italic>
###xml 415 420 <span type="species:ncbi:4932">yeast</span>
Another candidate for the dislocation channel is Sec61p, which is a core component of the translocation channel through which proteins are imported into the ER (8). A number of observations support a role for Sec61p in ERAD including its association with a variety of ERAD substrates (9-11) plus the intriguing observation that proteasomes interact with the Sec61 complex both in vivo and in vitro (12). Studies in yeast have shown that the degradation of an unfolded mutant form of alpha factor is reduced in a cell free assay using microsomes from various sec61 mutant strains (13), whereas the degradation of CPY* is delayed in sec61-2 mutant cells (14). However, the interpretation of these data is complicated by the fact that the sec61 mutant alleles examined were also defective in the initial translocation of both alpha factor and CPY*.
###end p 11
###begin p 12
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
In this paper we employ the sec61-3 mutant, which has a cold-sensitive defect in the signal recognition particle (SRP)-dependent co-translational translocation pathway. We therefore engineered two novel SRP-dependent derivatives of CPY*, one integral membrane form and one soluble, and examined their translocation and ERAD properties. We demonstrate that Sec61p is required for ERAD of these novel substrates in a manner that is independent of any effect on translocation.
###end p 12
###begin title 13
EXPERIMENTAL PROCEDURES
###end title 13
###begin p 14
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Yeast Strains</italic>
###xml 59 66 59 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl1">Table 1</xref>
###xml 432 436 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1</italic>
###xml 438 443 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KANMX</italic>
###xml 510 517 504 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 569 576 563 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 613 615 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref15">15</xref>
###xml 692 699 686 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="tbl2">Table 2</xref>
###xml 756 763 750 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 1059 1066 1053 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
###xml 68 73 <span type="species:ncbi:4932">Yeast</span>
###xml 130 135 <span type="species:ncbi:4932">yeast</span>
###xml 182 187 <span type="species:ncbi:4932">yeast</span>
###xml 913 918 <span type="species:ncbi:4932">yeast</span>
Yeast Strains-The strains used in this study are listed in Table 1. Yeast strains were grown in either YPD medium (2% peptone, 1% yeast extract, 2% glucose) or minimal medium (0.67% yeast nitrogen base, 2% glucose, appropriate supplements) at temperatures required for individual experiments (17, 24, 30, or 37 degreesC). Analysis of plasmid-borne forms of CPY*, DPY*, and OPY* were performed in strains lacking any endogenous CPY (prc1::KANMX). To make strains of the required genotypes, we re-engineered the sec61-3 allele in target strains in the following way. The sec61-3 mutation was introduced into pBW11 (15) by site-directed mutagenesis with Primers 1 and 2 generating plasmid pCW11 Table 2. A 2.4-kb KpnI-PstI fragment containing the mutagenized sec61-3 allele was cloned into KpnI-PstI of YIp352, generating an integrative vector pCW14, which was subsequently linearized with Xba1 and transformed into yeast. Loss of the integrative vector part was selected for on media containing 5-fluo-orotic acid, and the resulting single copy genomic copy of sec61-3 was confirmed by PCR and DNA sequencing.
###end p 14
###begin p 15
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 1</label>
###xml 7 39 7 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yeast strains used in this study</bold>
###xml 7 39 7 39 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16"><bold>Yeast strains used in this study</bold></p>
###xml 7 39 7 39 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16"><bold>Yeast strains used in this study</bold></p></caption>
###xml 39 45 39 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Strain</bold>
###xml 39 45 39 45 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Strain</bold></th>
###xml 45 53 45 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</bold>
###xml 45 53 45 53 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Genotype</bold></th>
###xml 53 59 53 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Source</bold>
###xml 53 59 53 59 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Source</bold></th>
###xml 39 59 39 59 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Strain</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Genotype</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Source</bold></th></tr>
###xml 39 59 39 59 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Strain</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Genotype</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Source</bold></th></tr></thead>
###xml 59 66 59 66 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> MWY61 </td>
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 70 79 70 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1::Kan</italic>
###xml 82 106 82 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 his3 trp1 ura3 der1</italic>
###xml 66 114 66 114 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 der1</italic>::KanMX </td>
###xml 114 126 114 126 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 59 126 59 126 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> MWY61 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 der1</italic>::KanMX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 126 133 126 133 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> MWY63 </td>
###xml 133 136 133 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 136 137 136 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 137 146 137 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1::Kan</italic>
###xml 149 183 149 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 his3 ura3 ade2 pep4-3 sec61-3</italic>
###xml 133 183 133 183 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 ade2 pep4-3 sec61-3</italic></td>
###xml 183 195 183 195 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 126 195 126 195 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> MWY63 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 ade2 pep4-3 sec61-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 195 202 195 202 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> MWY64 </td>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 205 206 205 206 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 206 215 206 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1::Kan</italic>
###xml 218 239 218 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 ura3 ade2 pep4-3</italic>
###xml 202 239 202 239 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 ura3 ade2 pep4-3</italic></td>
###xml 239 251 239 251 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 195 251 195 251 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> MWY64 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 ura3 ade2 pep4-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 251 258 251 258 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> MWY71 </td>
###xml 258 261 258 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 261 262 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 262 271 262 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1::Kan</italic>
###xml 274 306 274 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 his3 trp1 ura3 ade2 sec65-1</italic>
###xml 258 306 258 306 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec65-1</italic></td>
###xml 306 318 306 318 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 251 318 251 318 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> MWY71 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec65-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 318 325 318 325 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> MWY77 </td>
###xml 325 328 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 328 329 328 329 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 329 338 329 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1::Kan</italic>
###xml 341 366 341 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 his3 ura3 doa10::Kan</italic>
###xml 325 369 325 369 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 doa10::Kan</italic>MX </td>
###xml 369 381 369 381 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 318 381 318 381 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> MWY77 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 doa10::Kan</italic>MX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 381 388 381 388 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> MWY82 </td>
###xml 388 391 388 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 391 392 391 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 392 401 392 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1::Kan</italic>
###xml 404 436 404 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 his3 trp1 ura3 ade2 sec62-1</italic>
###xml 388 436 388 436 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec62-1</italic></td>
###xml 436 448 436 448 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 381 448 381 448 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> MWY82 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec62-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 448 458 448 458 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> W303-cd3 </td>
###xml 458 461 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mat</italic>
###xml 463 499 463 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">leu2 his3 trp1 ura3 ade2 der3 prc1-1</italic>
###xml 458 499 458 499 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic>a <italic>leu2 his3 trp1 ura3 ade2 der3 prc1-1</italic></td>
###xml 499 511 499 511 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"> This study </td>
###xml 448 511 448 511 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> W303-cd3 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic>a <italic>leu2 his3 trp1 ura3 ade2 der3 prc1-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr>
###xml 59 511 59 511 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY61 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 der1</italic>::KanMX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY63 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 ade2 pep4-3 sec61-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY64 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 ura3 ade2 pep4-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY71 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec65-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY77 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 doa10::Kan</italic>MX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY82 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec62-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> W303-cd3 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic>a <italic>leu2 his3 trp1 ura3 ade2 der3 prc1-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr></tbody>
###xml 39 511 39 511 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Strain</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Genotype</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Source</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY61 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 der1</italic>::KanMX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY63 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 ade2 pep4-3 sec61-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY64 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 ura3 ade2 pep4-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY71 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec65-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY77 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 doa10::Kan</italic>MX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY82 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec62-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> W303-cd3 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic>a <italic>leu2 his3 trp1 ura3 ade2 der3 prc1-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr></tbody></table>
###xml 0 511 0 511 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl1"><label>TABLE 1</label><caption><p textid="16"><bold>Yeast strains used in this study</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Strain</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Genotype</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Source</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY61 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 der1</italic>::KanMX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY63 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 ade2 pep4-3 sec61-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY64 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 ura3 ade2 pep4-3</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY71 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec65-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY77 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 ura3 doa10::Kan</italic>MX </td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> MWY82 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic><bold>a</bold><italic>prc1::Kan</italic>MX <italic>leu2 his3 trp1 ura3 ade2 sec62-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> W303-cd3 </td><td colspan="1" rowspan="1" align="left" valign="top"><italic>Mat</italic>a <italic>leu2 his3 trp1 ura3 ade2 der3 prc1-1</italic></td><td colspan="1" rowspan="1" align="center" valign="top"> This study </td></tr></tbody></table></table-wrap>
TABLE 1Yeast strains used in this studyStrainGenotypeSource MWY61 Mataprc1::KanMX leu2 his3 trp1 ura3 der1::KanMX  This study  MWY63 Mataprc1::KanMX leu2 his3 ura3 ade2 pep4-3 sec61-3 This study  MWY64 Mataprc1::KanMX leu2 ura3 ade2 pep4-3 This study  MWY71 Mataprc1::KanMX leu2 his3 trp1 ura3 ade2 sec65-1 This study  MWY77 Mataprc1::KanMX leu2 his3 ura3 doa10::KanMX  This study  MWY82 Mataprc1::KanMX leu2 his3 trp1 ura3 ade2 sec62-1 This study  W303-cd3 Mata leu2 his3 trp1 ura3 ade2 der3 prc1-1 This study 
###end p 15
###begin p 16
###xml 0 32 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Yeast strains used in this study</bold>
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast strains used in this study
###end p 16
###begin p 17
###xml 0 7 0 7 <label xmlns:xlink="http://www.w3.org/1999/xlink">TABLE 2</label>
###xml 7 42 7 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Oligonucleotides used in this study</bold>
###xml 7 42 7 42 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><bold>Oligonucleotides used in this study</bold></p>
###xml 7 42 7 42 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><bold>Oligonucleotides used in this study</bold></p></caption>
###xml 42 46 42 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Name</bold>
###xml 42 46 42 46 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Name</bold></th>
###xml 46 54 46 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequence</bold>
###xml 46 54 46 54 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="center" valign="top"><bold>Sequence</bold></th>
###xml 42 54 42 54 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="1" rowspan="1" align="center" valign="top"><bold>Name</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Sequence</bold></th></tr>
###xml 42 54 42 54 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Name</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Sequence</bold></th></tr></thead>
###xml 54 64 54 64 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> prc1-1_F </td>
###xml 64 106 64 106 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CCGAGCTCGCGATGTTGGTCATCCAGTACACTTCGGTAGC </td>
###xml 54 106 54 106 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGAGCTCGCGATGTTGGTCATCCAGTACACTTCGGTAGC </td></tr>
###xml 106 116 106 116 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> prc1-1_R </td>
###xml 116 150 116 150 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> GGAATCAGCACATAGTTCTTGAACCAGCTCAG </td>
###xml 106 150 106 150 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> GGAATCAGCACATAGTTCTTGAACCAGCTCAG </td></tr>
###xml 150 162 150 162 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_F </td>
###xml 162 217 162 217 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CTACTCAACTTAAAGTATACATACCATATGAAAGCATTCACCAGTTTACTATG </td>
###xml 150 217 150 217 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CTACTCAACTTAAAGTATACATACCATATGAAAGCATTCACCAGTTTACTATG </td></tr>
###xml 217 229 217 229 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_R </td>
###xml 229 284 229 284 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CATAGTAAACTGGTGAATGCTTTCATATGGTATGTATACTTTAAGTTGAGTAG </td>
###xml 217 284 217 284 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> CATAGTAAACTGGTGAATGCTTTCATATGGTATGTATACTTTAAGTTGAGTAG </td></tr>
###xml 284 294 284 294 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> DPAPB_F2 </td>
###xml 294 350 294 350 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> GAGGACATATGAGAGTCGGTATTATCTTCGTTTTGTTGATTTGGGGTACTGTTT </td>
###xml 284 350 284 350 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_F2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GAGGACATATGAGAGTCGGTATTATCTTCGTTTTGTTGATTTGGGGTACTGTTT </td></tr>
###xml 350 360 350 360 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> DPAPB_R2 </td>
###xml 360 416 360 416 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> GTGCCGTAGGCCTTCTATACTCTTCAACAACAAAACAGTACCCAAAATCAACAA </td>
###xml 350 416 350 416 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_R2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GTGCCGTAGGCCTTCTATACTCTTCAACAACAAAACAGTACCCAAAATCAACAA </td></tr>
###xml 416 423 416 423 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> OST2F </td>
###xml 423 467 423 467 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> TTCTTTGAGCTCCGAGGCAGCAGTCTCTGTGGAGGGGGTACC </td>
###xml 416 467 416 467 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> OST2F </td><td colspan="1" rowspan="1" align="left" valign="top"> TTCTTTGAGCTCCGAGGCAGCAGTCTCTGTGGAGGGGGTACC </td></tr>
###xml 467 474 467 474 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> OST2R </td>
###xml 474 527 474 527 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CCGGATATCGGCTCGTATTGGGCAGCAGAAGACACGTTGAAAAAACATAGG </td>
###xml 467 527 467 527 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> OST2R </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGGATATCGGCTCGTATTGGGCAGCAGAAGACACGTTGAAAAAACATAGG </td></tr>
###xml 527 537 527 537 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Primer 1 </td>
###xml 537 579 537 579 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> CTCAAATGGCCTTGAGCGAGTTGGCCTACTACATCCAACC </td>
###xml 527 579 527 579 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Primer 1 </td><td colspan="1" rowspan="1" align="left" valign="top"> CTCAAATGGCCTTGAGCGAGTTGGCCTACTACATCCAACC </td></tr>
###xml 579 589 579 589 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> Primer 2 </td>
###xml 589 631 589 631 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="1" rowspan="1" align="left" valign="top"> GGTTGGATGTAGTAGGCCAACTCGCTCAAGGCCATTTGAG </td>
###xml 579 631 579 631 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td colspan="1" rowspan="1" align="left" valign="top"> Primer 2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GGTTGGATGTAGTAGGCCAACTCGCTCAAGGCCATTTGAG </td></tr>
###xml 54 631 54 631 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGAGCTCGCGATGTTGGTCATCCAGTACACTTCGGTAGC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> GGAATCAGCACATAGTTCTTGAACCAGCTCAG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CTACTCAACTTAAAGTATACATACCATATGAAAGCATTCACCAGTTTACTATG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> CATAGTAAACTGGTGAATGCTTTCATATGGTATGTATACTTTAAGTTGAGTAG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_F2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GAGGACATATGAGAGTCGGTATTATCTTCGTTTTGTTGATTTGGGGTACTGTTT </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_R2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GTGCCGTAGGCCTTCTATACTCTTCAACAACAAAACAGTACCCAAAATCAACAA </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> OST2F </td><td colspan="1" rowspan="1" align="left" valign="top"> TTCTTTGAGCTCCGAGGCAGCAGTCTCTGTGGAGGGGGTACC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> OST2R </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGGATATCGGCTCGTATTGGGCAGCAGAAGACACGTTGAAAAAACATAGG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Primer 1 </td><td colspan="1" rowspan="1" align="left" valign="top"> CTCAAATGGCCTTGAGCGAGTTGGCCTACTACATCCAACC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Primer 2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GGTTGGATGTAGTAGGCCAACTCGCTCAAGGCCATTTGAG </td></tr></tbody>
###xml 42 631 42 631 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Name</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Sequence</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGAGCTCGCGATGTTGGTCATCCAGTACACTTCGGTAGC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> GGAATCAGCACATAGTTCTTGAACCAGCTCAG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CTACTCAACTTAAAGTATACATACCATATGAAAGCATTCACCAGTTTACTATG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> CATAGTAAACTGGTGAATGCTTTCATATGGTATGTATACTTTAAGTTGAGTAG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_F2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GAGGACATATGAGAGTCGGTATTATCTTCGTTTTGTTGATTTGGGGTACTGTTT </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_R2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GTGCCGTAGGCCTTCTATACTCTTCAACAACAAAACAGTACCCAAAATCAACAA </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> OST2F </td><td colspan="1" rowspan="1" align="left" valign="top"> TTCTTTGAGCTCCGAGGCAGCAGTCTCTGTGGAGGGGGTACC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> OST2R </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGGATATCGGCTCGTATTGGGCAGCAGAAGACACGTTGAAAAAACATAGG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Primer 1 </td><td colspan="1" rowspan="1" align="left" valign="top"> CTCAAATGGCCTTGAGCGAGTTGGCCTACTACATCCAACC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Primer 2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GGTTGGATGTAGTAGGCCAACTCGCTCAAGGCCATTTGAG </td></tr></tbody></table>
###xml 0 631 0 631 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="tbl2"><label>TABLE 2</label><caption><p textid="18"><bold>Oligonucleotides used in this study</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1" align="center" valign="top"><bold>Name</bold></th><th colspan="1" rowspan="1" align="center" valign="top"><bold>Sequence</bold></th></tr></thead><tbody><tr><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGAGCTCGCGATGTTGGTCATCCAGTACACTTCGGTAGC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> prc1-1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> GGAATCAGCACATAGTTCTTGAACCAGCTCAG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_F </td><td colspan="1" rowspan="1" align="left" valign="top"> CTACTCAACTTAAAGTATACATACCATATGAAAGCATTCACCAGTTTACTATG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> CPY_Nde1_R </td><td colspan="1" rowspan="1" align="left" valign="top"> CATAGTAAACTGGTGAATGCTTTCATATGGTATGTATACTTTAAGTTGAGTAG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_F2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GAGGACATATGAGAGTCGGTATTATCTTCGTTTTGTTGATTTGGGGTACTGTTT </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> DPAPB_R2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GTGCCGTAGGCCTTCTATACTCTTCAACAACAAAACAGTACCCAAAATCAACAA </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> OST2F </td><td colspan="1" rowspan="1" align="left" valign="top"> TTCTTTGAGCTCCGAGGCAGCAGTCTCTGTGGAGGGGGTACC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> OST2R </td><td colspan="1" rowspan="1" align="left" valign="top"> CCGGATATCGGCTCGTATTGGGCAGCAGAAGACACGTTGAAAAAACATAGG </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Primer 1 </td><td colspan="1" rowspan="1" align="left" valign="top"> CTCAAATGGCCTTGAGCGAGTTGGCCTACTACATCCAACC </td></tr><tr><td colspan="1" rowspan="1" align="left" valign="top"> Primer 2 </td><td colspan="1" rowspan="1" align="left" valign="top"> GGTTGGATGTAGTAGGCCAACTCGCTCAAGGCCATTTGAG </td></tr></tbody></table></table-wrap>
TABLE 2Oligonucleotides used in this studyNameSequence prc1-1_F  CCGAGCTCGCGATGTTGGTCATCCAGTACACTTCGGTAGC  prc1-1_R  GGAATCAGCACATAGTTCTTGAACCAGCTCAG  CPY_Nde1_F  CTACTCAACTTAAAGTATACATACCATATGAAAGCATTCACCAGTTTACTATG  CPY_Nde1_R  CATAGTAAACTGGTGAATGCTTTCATATGGTATGTATACTTTAAGTTGAGTAG  DPAPB_F2  GAGGACATATGAGAGTCGGTATTATCTTCGTTTTGTTGATTTGGGGTACTGTTT  DPAPB_R2  GTGCCGTAGGCCTTCTATACTCTTCAACAACAAAACAGTACCCAAAATCAACAA  OST2F  TTCTTTGAGCTCCGAGGCAGCAGTCTCTGTGGAGGGGGTACC  OST2R  CCGGATATCGGCTCGTATTGGGCAGCAGAAGACACGTTGAAAAAACATAGG  Primer 1  CTCAAATGGCCTTGAGCGAGTTGGCCTACTACATCCAACC  Primer 2  GGTTGGATGTAGTAGGCCAACTCGCTCAAGGCCATTTGAG 
###end p 17
###begin p 18
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Oligonucleotides used in this study</bold>
Oligonucleotides used in this study
###end p 18
###begin p 19
###xml 0 21 0 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Plasmid Constructions</italic>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PRC1</italic>
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prc1-1</italic>
###xml 1064 1071 1064 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 1123 1130 1123 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
Plasmid Constructions-Plasmids encoding CPY* (pMW319), DPY* (pMW339), and OPY* (pMW342) were generated as follows. The CPY* encoding allele of PRC1 (prc1-1) was amplified from genomic DNA with primers prc1-1_F and prc1-1_R. A 2379-bp HindIII-SacI DNA fragment was cloned into pRS315 and pRS316 to generate pMW319 and pMW320, respectively. A 645-bp BamHI-SacI fragment from pMW320 was cloned into pBLUESCRIPT KS+ to generate pMW321. A NdeI restriction site was introduced by site-directed mutagenesis with primers CPY_NdeI_F and CPY_NdeI_R to generate pMW325. Signal sequence coding sequence of DPAP B was amplified with primers DPAPB_F2 and DPAPB_R2 and following digestion with NdeI and StuI cloned into pMW325 to generate pMW330. Finally, a 748-bp SacI-BamHI fragment from was cloned from pMW330 into pMW319 to generate pMW339. An OST1 sequence was PCR-amplified with primers OST2F and OST2R, digested with SacI and EcoRV, and cloned into SacI-StuI of pMW319 to generate pMW342. To be able to make strains of the required genotypes, we decided to regenerate the sec61-3 allele in target strains in the following way: The sec61-3 mutation was introduced into pBW11(22) by site-directed mutagenesis with Primers 1 and 2 generating plasmid pCW11. A 2.4-kb KpnI-PstI fragment was cloned into YIp352, generating pCW14.
###end p 19
###begin p 20
###xml 0 32 0 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Membrane Association Experiments</italic>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref16">16</xref>
###xml 130 131 130 131 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 134 135 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 186 187 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 383 385 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
###xml 386 388 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref20">20</xref>
Membrane Association Experiments-The microsomes were prepared as previously described (16). The microsomes were treated with 100 mm Na2CO3 at 0 degreesC for 30 min and spun at 100,000 x g for 60 min. Equal proportions of pellets and supernatants were analyzed by Western blotting with appropriate antibodies. Antibodies against CPY, Kar2p, and Sec61p have previously been described (17-20).
###end p 20
###begin p 21
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pulse-Chase Analysis</italic>
###xml 124 125 124 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 125 128 125 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600</sub>
###xml 153 155 153 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 327 328 327 328 <sc xmlns:xlink="http://www.w3.org/1999/xlink">m</sc>
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 338 341 338 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600</sub>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref17">17</xref>
Pulse-Chase Analysis-Temperature shifts were done for 2 h prior to radiolabeling. The cells were grown in minimal medium to A600 = 0.2 and labeled with [35S]methionine for 20 min (5 min for experiments looking at translocation). Chase was performed by the addition of cold methionine and cysteine to final concentrations of 2 mm each. 5 A600 units of cells were taken for each time point, and the cell extracts were prepared for immunoprecipitation as described (17). Radiolabeled proteins were visualized using a Fujifilm FLA3000 phosphorimaging device, and quantitation was performed on signals within the linear range of detection using the Aida Image Analyzer v.3.44 software.
###end p 21
###begin title 22
RESULTS
###end title 22
###begin p 23
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Properties of New ERAD Substrates</italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref21">21</xref>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61</italic>
###xml 476 483 476 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 831 832 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 825 832 813 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 924 931 912 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 67 72 <span type="species:ncbi:4932">yeast</span>
Properties of New ERAD Substrates-A single mutation (G255R) in the yeast vacuolar protease carboxypeptidase Y (CPY) results in a misfolded protein (CPY*), which is a substrate for the ERAD-L pathway (21). PreproCPY* is translated in the cytosol and translocated post-translationally into the ER. We were interested in addressing the role of Sec61p in ERAD using CPY* as a substrate, but all known mutant alleles of sec61 are deficient in post-translational translocation. The sec61-3 mutant allele is no exception but differs in that it also exhibits a cold-sensitive defect in co-translational translocation. This mutant translocates SRP-dependent precursors efficiently at 30 degreesC but is defective in post-translational translocation at this temperature and is completely deficient in all translocation at 17 degreesC (Fig. 1A). We therefore reasoned that an SRP-dependent ERAD substrate might translocate normally in sec61-3 cells at 30 degreesC and might therefore allow us to test specifically for any effect on ERAD following the loss of Sec61p function at 17 degreesC.
###end p 23
###begin p 24
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref22">22</xref>
###xml 338 339 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 332 339 332 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref24">24</xref>
The signal sequence of a precursor determines whether it will follow either the Sec62- or SRP-dependent pathway, with more hydrophobic sequences tending to require the latter (22). We therefore sought to create SRP-dependent derivatives of CPY* by replacing its targeting sequence with that of either DPAP-B (DPY*) or Ost1p (OPY*) (Fig. 1B). DPAP-B is a type II integral membrane protein with an amino-terminal signal anchor domain whose targeting is SRP-dependent (23). Ost1p is a type I integral membrane protein with a cleavable signal sequence (24) whose hydrophobicity led us to predict a likely dependence upon SRP.
###end p 24
###begin p 25
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 1.</label>
###xml 9 58 9 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Translocation properties of CPY*, DPY*, and OPY*.</bold>
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC61</italic>
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 222 223 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 570 571 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 696 705 684 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black dot</italic>
###xml 789 795 777 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 880 881 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 951 958 939 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 981 985 969 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. D</italic>
###xml 998 1000 986 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 1003 1010 991 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 1021 1028 1009 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec65-1</italic>
###xml 9 1240 9 1216 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="26"><bold>Translocation properties of CPY*, DPY*, and OPY*.</bold><italic>A</italic>, wild type (<italic>SEC61</italic>) cells and <italic>sec61-3</italic> mutant cells each expressing CPY* were grown at 30 &#176;C and either shifted to 17 &#176;C or incubated with tunicamycin (<italic>T</italic>) for 2 h prior to radiolabeling as described under &#8220;Experimental Procedures.&#8221; Immunoprecipitated forms of CPY* and DPAP B were analyzed by SDS-PAGE: translocated glycosylated forms (g-pCPY* and mDPAP B), translocated but unglycosylated forms upon treatment with tunicamycin (pCPY* and pDPAP B), and untranslocated precursor (ppCPY* and pDPAP B). <italic>B</italic>, schematic representation of the three substrates used in this study. All are based on CPY* and contain the G255R mutation (<italic>black dot</italic>), which prevents CPY* folding. Predicted signal sequence cleavage sites indicated (<italic>arrows</italic>), DPY* has the DPAP B signal sequence, and OPY* has the signal sequence from Ost1p. <italic>C</italic>, translocation of CPY*, DPY*, and OPY* was analyzed in wild type and <italic>sec61-3</italic> cells as described in <italic>A. D</italic>, wild type (<italic>WT</italic>), <italic>sec62-1</italic> cells, or <italic>sec65-1</italic> cells expressing either CPY*, DPY*, or OPY* were grown at 24 &#176;C and then either shifted to 37 &#176;C for 1 h or treated with tunicamycin prior to radiolabeling and immunoprecipitation as described above.</p>
###xml 9 1240 9 1216 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26"><bold>Translocation properties of CPY*, DPY*, and OPY*.</bold><italic>A</italic>, wild type (<italic>SEC61</italic>) cells and <italic>sec61-3</italic> mutant cells each expressing CPY* were grown at 30 &#176;C and either shifted to 17 &#176;C or incubated with tunicamycin (<italic>T</italic>) for 2 h prior to radiolabeling as described under &#8220;Experimental Procedures.&#8221; Immunoprecipitated forms of CPY* and DPAP B were analyzed by SDS-PAGE: translocated glycosylated forms (g-pCPY* and mDPAP B), translocated but unglycosylated forms upon treatment with tunicamycin (pCPY* and pDPAP B), and untranslocated precursor (ppCPY* and pDPAP B). <italic>B</italic>, schematic representation of the three substrates used in this study. All are based on CPY* and contain the G255R mutation (<italic>black dot</italic>), which prevents CPY* folding. Predicted signal sequence cleavage sites indicated (<italic>arrows</italic>), DPY* has the DPAP B signal sequence, and OPY* has the signal sequence from Ost1p. <italic>C</italic>, translocation of CPY*, DPY*, and OPY* was analyzed in wild type and <italic>sec61-3</italic> cells as described in <italic>A. D</italic>, wild type (<italic>WT</italic>), <italic>sec62-1</italic> cells, or <italic>sec65-1</italic> cells expressing either CPY*, DPY*, or OPY* were grown at 24 &#176;C and then either shifted to 37 &#176;C for 1 h or treated with tunicamycin prior to radiolabeling and immunoprecipitation as described above.</p></caption>
###xml 1240 1240 1216 1216 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0510857770001"/>
###xml 0 1240 0 1216 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig1"><label>FIGURE 1.</label><caption><p textid="26"><bold>Translocation properties of CPY*, DPY*, and OPY*.</bold><italic>A</italic>, wild type (<italic>SEC61</italic>) cells and <italic>sec61-3</italic> mutant cells each expressing CPY* were grown at 30 &#176;C and either shifted to 17 &#176;C or incubated with tunicamycin (<italic>T</italic>) for 2 h prior to radiolabeling as described under &#8220;Experimental Procedures.&#8221; Immunoprecipitated forms of CPY* and DPAP B were analyzed by SDS-PAGE: translocated glycosylated forms (g-pCPY* and mDPAP B), translocated but unglycosylated forms upon treatment with tunicamycin (pCPY* and pDPAP B), and untranslocated precursor (ppCPY* and pDPAP B). <italic>B</italic>, schematic representation of the three substrates used in this study. All are based on CPY* and contain the G255R mutation (<italic>black dot</italic>), which prevents CPY* folding. Predicted signal sequence cleavage sites indicated (<italic>arrows</italic>), DPY* has the DPAP B signal sequence, and OPY* has the signal sequence from Ost1p. <italic>C</italic>, translocation of CPY*, DPY*, and OPY* was analyzed in wild type and <italic>sec61-3</italic> cells as described in <italic>A. D</italic>, wild type (<italic>WT</italic>), <italic>sec62-1</italic> cells, or <italic>sec65-1</italic> cells expressing either CPY*, DPY*, or OPY* were grown at 24 &#176;C and then either shifted to 37 &#176;C for 1 h or treated with tunicamycin prior to radiolabeling and immunoprecipitation as described above.</p></caption><graphic xlink:href="zbc0510857770001"/></fig>
FIGURE 1.Translocation properties of CPY*, DPY*, and OPY*.A, wild type (SEC61) cells and sec61-3 mutant cells each expressing CPY* were grown at 30 degreesC and either shifted to 17 degreesC or incubated with tunicamycin (T) for 2 h prior to radiolabeling as described under "Experimental Procedures." Immunoprecipitated forms of CPY* and DPAP B were analyzed by SDS-PAGE: translocated glycosylated forms (g-pCPY* and mDPAP B), translocated but unglycosylated forms upon treatment with tunicamycin (pCPY* and pDPAP B), and untranslocated precursor (ppCPY* and pDPAP B). B, schematic representation of the three substrates used in this study. All are based on CPY* and contain the G255R mutation (black dot), which prevents CPY* folding. Predicted signal sequence cleavage sites indicated (arrows), DPY* has the DPAP B signal sequence, and OPY* has the signal sequence from Ost1p. C, translocation of CPY*, DPY*, and OPY* was analyzed in wild type and sec61-3 cells as described in A. D, wild type (WT), sec62-1 cells, or sec65-1 cells expressing either CPY*, DPY*, or OPY* were grown at 24 degreesC and then either shifted to 37 degreesC for 1 h or treated with tunicamycin prior to radiolabeling and immunoprecipitation as described above.
###end p 25
###begin p 26
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Translocation properties of CPY*, DPY*, and OPY*.</bold>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SEC61</italic>
###xml 80 87 80 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 213 214 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 561 562 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 687 696 675 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black dot</italic>
###xml 780 786 768 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 871 872 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 942 949 930 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 972 976 960 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. D</italic>
###xml 989 991 977 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WT</italic>
###xml 994 1001 982 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 1012 1019 1000 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec65-1</italic>
Translocation properties of CPY*, DPY*, and OPY*.A, wild type (SEC61) cells and sec61-3 mutant cells each expressing CPY* were grown at 30 degreesC and either shifted to 17 degreesC or incubated with tunicamycin (T) for 2 h prior to radiolabeling as described under "Experimental Procedures." Immunoprecipitated forms of CPY* and DPAP B were analyzed by SDS-PAGE: translocated glycosylated forms (g-pCPY* and mDPAP B), translocated but unglycosylated forms upon treatment with tunicamycin (pCPY* and pDPAP B), and untranslocated precursor (ppCPY* and pDPAP B). B, schematic representation of the three substrates used in this study. All are based on CPY* and contain the G255R mutation (black dot), which prevents CPY* folding. Predicted signal sequence cleavage sites indicated (arrows), DPY* has the DPAP B signal sequence, and OPY* has the signal sequence from Ost1p. C, translocation of CPY*, DPY*, and OPY* was analyzed in wild type and sec61-3 cells as described in A. D, wild type (WT), sec62-1 cells, or sec65-1 cells expressing either CPY*, DPY*, or OPY* were grown at 24 degreesC and then either shifted to 37 degreesC for 1 h or treated with tunicamycin prior to radiolabeling and immunoprecipitation as described above.
###end p 26
###begin p 27
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 2.</label>
###xml 9 59 9 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Membrane association of novel derivatives of CPY*.</bold>
###xml 143 144 143 144 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 213 214 213 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 9 338 9 338 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28"><bold>Membrane association of novel derivatives of CPY*.</bold> Microsomes from wild type cells expressing CPY*, DPY*, or OPY* were treated with Na<sub>2</sub>CO<sub>3</sub> as described under &#8220;Experimental Procedures.&#8221; Total (<italic>T</italic>), pellet (<italic>P</italic>), and supernatant (<italic>S</italic>) fractions were analyzed by Western blots using antibodies against CPY, Kar2p, or Sec61p as indicated.</p>
###xml 9 338 9 338 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28"><bold>Membrane association of novel derivatives of CPY*.</bold> Microsomes from wild type cells expressing CPY*, DPY*, or OPY* were treated with Na<sub>2</sub>CO<sub>3</sub> as described under &#8220;Experimental Procedures.&#8221; Total (<italic>T</italic>), pellet (<italic>P</italic>), and supernatant (<italic>S</italic>) fractions were analyzed by Western blots using antibodies against CPY, Kar2p, or Sec61p as indicated.</p></caption>
###xml 338 338 338 338 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0510857770002"/>
###xml 0 338 0 338 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig2"><label>FIGURE 2.</label><caption><p textid="28"><bold>Membrane association of novel derivatives of CPY*.</bold> Microsomes from wild type cells expressing CPY*, DPY*, or OPY* were treated with Na<sub>2</sub>CO<sub>3</sub> as described under &#8220;Experimental Procedures.&#8221; Total (<italic>T</italic>), pellet (<italic>P</italic>), and supernatant (<italic>S</italic>) fractions were analyzed by Western blots using antibodies against CPY, Kar2p, or Sec61p as indicated.</p></caption><graphic xlink:href="zbc0510857770002"/></fig>
FIGURE 2.Membrane association of novel derivatives of CPY*. Microsomes from wild type cells expressing CPY*, DPY*, or OPY* were treated with Na2CO3 as described under "Experimental Procedures." Total (T), pellet (P), and supernatant (S) fractions were analyzed by Western blots using antibodies against CPY, Kar2p, or Sec61p as indicated.
###end p 27
###begin p 28
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Membrane association of novel derivatives of CPY*.</bold>
###xml 134 135 134 135 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 225 226 225 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
Membrane association of novel derivatives of CPY*. Microsomes from wild type cells expressing CPY*, DPY*, or OPY* were treated with Na2CO3 as described under "Experimental Procedures." Total (T), pellet (P), and supernatant (S) fractions were analyzed by Western blots using antibodies against CPY, Kar2p, or Sec61p as indicated.
###end p 28
###begin p 29
###xml 0 33 0 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ER Translocation of DPY* and OPY*</italic>
###xml 283 290 283 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 351 352 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 345 352 339 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>C</italic></xref>
###xml 549 556 537 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 635 642 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 877 884 865 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec65-1</italic>
###xml 943 945 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref23">23</xref>
###xml 1003 1010 991 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec65-1</italic>
###xml 1228 1229 1198 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1222 1229 1192 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 1444 1451 1414 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 1610 1612 1568 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref25">25</xref>
###xml 1671 1678 1629 1636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 1825 1826 1777 1778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1819 1826 1771 1778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1<italic>D</italic></xref>
###xml 1970 1977 1922 1929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
ER Translocation of DPY* and OPY*-When expressed in wild type cells, both DPY* and OPY* were efficiently translocated and glycosylated, indicating that their respective ER targeting signals are functional. Our hypothesis predicted that DPY* and OPY* would translocate efficiently in sec61-3 cells at 30 degreesC, and this proved to be the case (Fig. 1C). Interestingly, these proteins also translocate well at 17 degreesC, suggesting that the SRP-dependent targeting of a polypeptide that is competent for post-translational import can overcome the sec61-3 translocation defect. This finding suggested that the translocation defect in sec61-3 cells might be kinetic in nature, and this has been confirmed by pulse-chase analysis (see supplemental Fig. 1). To confirm that DPY* and OPY* were being targeted via the SRP-dependent pathway, we also examined their translocation in sec65-1 cells, which express a temperature-sensitive form of SRP (23). As expected, preproCPY* translocation is unaffected in sec65-1 cells with only the ER glycosylated form of proCPY* being evident at either 24 or 37 degreesC. In contrast, DPY* and OPY* translocate efficiently at 24 degreesC but accumulate as precursor forms at 37 degreesC (Fig. 1D). These results demonstrate that DPY* and OPY* require functional SRP for their ER targeting. A further characteristic of a genuinely SRP-dependent precursor is that it does not depend on Sec62p for translocation. sec62-1 cells have defects in post-translational translocation at their permissive temperature (24 degreesC) and are temperature-sensitive for growth at 37 degreesC (25). We therefore examined translocation of DPY* and OPY* in sec62-1 cells. A profound defect in translocation of CPY* was observed at both 24 and 37 degreesC, but DPY* and OPY* translocation were unaffected (Fig. 1D). We therefore conclude that unlike CPY*, both DPY* and OPY* translocate via the co-translational SRP-dependent pathway. Most importantly, the sec61-3 mutation has no detectable effect on translocation of these new precursors.
###end p 29
###begin p 30
###xml 0 37 0 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Membrane Association of DPY* and OPY*</italic>
Membrane Association of DPY* and OPY*-The signal peptide of preproCPY* is cleaved during translocation by signal peptidase.
###end p 30
###begin p 31
###xml 385 391 385 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2</xref>
OPY* was predicted to be similarly cleaved, whereas DPY* was predicted to insert into the bilayer as an integral membrane protein. To test these predictions we used carbonate extraction of microsomes to examine the membrane association of the various proteins. We found that DPY* behaved as an integral membrane protein, whereas both CPY* and OPY* were readily extracted by carbonate (Fig. 2). We therefore conclude that OPY* is soluble, whereas DPY* is membrane associated. DPY* and OPY* thus behave entirely differently from CPY* with regards to their mode of translocation and differently from one another with regards to their solubility/membrane association properties.
###end p 31
###begin p 32
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 3.</label>
###xml 9 66 9 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DPY* and OPY* are substrates for ERAD in wild type cells.</bold>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 141 143 141 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 426 427 426 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 461 462 461 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 9 463 9 463 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33"><bold>DPY* and OPY* are substrates for ERAD in wild type cells.</bold><italic>A</italic>, wild type cells expressing CPY*, DPY*, or OPY* were pulse-labeled with [<sup>35</sup>S]methionine as described under &#8220;Experimental Procedures.&#8221; After the addition of cold methionine (time 0), the samples were taken at 30 min intervals, whole cell extracts were subjected to immunoprecipitation with anti-CPY antibodies, and labeled proteins were analyzed by SDS-PAGE. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p>
###xml 9 463 9 463 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33"><bold>DPY* and OPY* are substrates for ERAD in wild type cells.</bold><italic>A</italic>, wild type cells expressing CPY*, DPY*, or OPY* were pulse-labeled with [<sup>35</sup>S]methionine as described under &#8220;Experimental Procedures.&#8221; After the addition of cold methionine (time 0), the samples were taken at 30 min intervals, whole cell extracts were subjected to immunoprecipitation with anti-CPY antibodies, and labeled proteins were analyzed by SDS-PAGE. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p></caption>
###xml 463 463 463 463 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0510857770003"/>
###xml 0 463 0 463 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig3"><label>FIGURE 3.</label><caption><p textid="33"><bold>DPY* and OPY* are substrates for ERAD in wild type cells.</bold><italic>A</italic>, wild type cells expressing CPY*, DPY*, or OPY* were pulse-labeled with [<sup>35</sup>S]methionine as described under &#8220;Experimental Procedures.&#8221; After the addition of cold methionine (time 0), the samples were taken at 30 min intervals, whole cell extracts were subjected to immunoprecipitation with anti-CPY antibodies, and labeled proteins were analyzed by SDS-PAGE. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p></caption><graphic xlink:href="zbc0510857770003"/></fig>
FIGURE 3.DPY* and OPY* are substrates for ERAD in wild type cells.A, wild type cells expressing CPY*, DPY*, or OPY* were pulse-labeled with [35S]methionine as described under "Experimental Procedures." After the addition of cold methionine (time 0), the samples were taken at 30 min intervals, whole cell extracts were subjected to immunoprecipitation with anti-CPY antibodies, and labeled proteins were analyzed by SDS-PAGE. B, quantification of data shown in A.
###end p 32
###begin p 33
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">DPY* and OPY* are substrates for ERAD in wild type cells.</bold>
###xml 57 58 57 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 132 134 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 417 418 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
DPY* and OPY* are substrates for ERAD in wild type cells.A, wild type cells expressing CPY*, DPY*, or OPY* were pulse-labeled with [35S]methionine as described under "Experimental Procedures." After the addition of cold methionine (time 0), the samples were taken at 30 min intervals, whole cell extracts were subjected to immunoprecipitation with anti-CPY antibodies, and labeled proteins were analyzed by SDS-PAGE. B, quantification of data shown in A.
###end p 33
###begin p 34
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 4.</label>
###xml 9 50 9 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY* is Der1p-dependent.</bold>
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 72 76 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">der1</italic>
###xml 140 141 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 134 141 130 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 143 144 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 178 179 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 9 180 9 176 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><bold>ERAD of DPY* and OPY* is Der1p-dependent.</bold><italic>A</italic>, wild type and &#916;<italic>der1</italic> cells expressing CPY*, DPY*, or OPY* were analyzed as in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p>
###xml 9 180 9 176 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35"><bold>ERAD of DPY* and OPY* is Der1p-dependent.</bold><italic>A</italic>, wild type and &#916;<italic>der1</italic> cells expressing CPY*, DPY*, or OPY* were analyzed as in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p></caption>
###xml 180 180 176 176 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0510857770004"/>
###xml 0 180 0 176 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig4"><label>FIGURE 4.</label><caption><p textid="35"><bold>ERAD of DPY* and OPY* is Der1p-dependent.</bold><italic>A</italic>, wild type and &#916;<italic>der1</italic> cells expressing CPY*, DPY*, or OPY* were analyzed as in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p></caption><graphic xlink:href="zbc0510857770004"/></fig>
FIGURE 4.ERAD of DPY* and OPY* is Der1p-dependent.A, wild type and Deltader1 cells expressing CPY*, DPY*, or OPY* were analyzed as in Fig. 3A. B, quantification of data shown in A.
###end p 34
###begin p 35
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY* is Der1p-dependent.</bold>
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 63 67 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">der1</italic>
###xml 131 132 127 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 125 132 121 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 134 135 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 169 170 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
ERAD of DPY* and OPY* is Der1p-dependent.A, wild type and Deltader1 cells expressing CPY*, DPY*, or OPY* were analyzed as in Fig. 3A. B, quantification of data shown in A.
###end p 35
###begin p 36
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 5.</label>
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 9 77 9 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY* is unaffected in <italic>sec61-3</italic> cells at 30 &#176;C.</bold>
###xml 77 78 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 123 130 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 174 175 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 168 175 156 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 177 178 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 212 213 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 9 214 9 202 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><bold>ERAD of DPY* and OPY* is unaffected in <italic>sec61-3</italic> cells at 30 &#176;C.</bold><italic>A</italic>, pulse-chase experiment using wild type and <italic>sec61-3</italic> cells at 30 &#176;C as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p>
###xml 9 214 9 202 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><bold>ERAD of DPY* and OPY* is unaffected in <italic>sec61-3</italic> cells at 30 &#176;C.</bold><italic>A</italic>, pulse-chase experiment using wild type and <italic>sec61-3</italic> cells at 30 &#176;C as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p></caption>
###xml 214 214 202 202 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0510857770005"/>
###xml 0 214 0 202 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig5"><label>FIGURE 5.</label><caption><p textid="37"><bold>ERAD of DPY* and OPY* is unaffected in <italic>sec61-3</italic> cells at 30 &#176;C.</bold><italic>A</italic>, pulse-chase experiment using wild type and <italic>sec61-3</italic> cells at 30 &#176;C as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>B</italic>, quantification of data shown in <italic>A</italic>.</p></caption><graphic xlink:href="zbc0510857770005"/></fig>
FIGURE 5.ERAD of DPY* and OPY* is unaffected in sec61-3 cells at 30 degreesC.A, pulse-chase experiment using wild type and sec61-3 cells at 30 degreesC as described in Fig. 3A. B, quantification of data shown in A.
###end p 36
###begin p 37
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 0 68 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY* is unaffected in <italic>sec61-3</italic> cells at 30 &#176;C.</bold>
###xml 68 69 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 114 121 108 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 165 166 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 159 166 147 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 168 169 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 203 204 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
ERAD of DPY* and OPY* is unaffected in sec61-3 cells at 30 degreesC.A, pulse-chase experiment using wild type and sec61-3 cells at 30 degreesC as described in Fig. 3A. B, quantification of data shown in A.
###end p 37
###begin p 38
###xml 0 51 0 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DPY* and OPY* Are Subject to Der1p-dependent ERAD-L</italic>
###xml 296 302 296 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3</xref>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 538 542 534 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">der1</italic>
###xml 628 634 624 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 868 870 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 872 874 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref27">27</xref>
###xml 1061 1067 1057 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4</xref>
###xml 1253 1258 1245 1250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">doa10</italic>
###xml 1344 1346 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref28">28</xref>
DPY* and OPY* Are Subject to Der1p-dependent ERAD-L-Next we examined whether the translocated forms of DPY* and OPY* were subject to ERAD. Wild type cells expressing CPY*, DPY*, or OPY* were subjected to pulse-chase studies demonstrating that all three substrates degraded with similar kinetics (Fig. 3). Signal cleaved OPY* behaved as a lumenal protein in our carbonate extraction studies, and so one might expect that it would be a substrate for the Der1p-dependent ERAD-L pathway (7). This was confirmed by pulse-chase studies in Deltader1 cells in which the rate of OPY* degradation was indistinguishable from that of CPY* (Fig. 4). DPY* shares the same lumenal lesion as CPY*/OPY* but in a membrane-tethered form. Recent studies suggest that ERAD-M can supersede the ERAD-L pathway for substrates that have lesions in both a membrane anchor and a lumenal domain (26, 27); thus any lesion in the DPY* membrane anchor might have led to degradation via the Der1p-independent ERAD-M pathway. However, our data demonstrate that DPY* degradation requires Der1p (Fig. 4) and so conclude that this degradation occurs as a result of the lumenal lesion in this protein. Finally we found that the rates of degradation of DPY* and OPY* were unaffected in Deltadoa10 cells (data not shown), confirming that neither was dependent on the ERAD-C pathway (28). We therefore conclude that DPY* and OPY* are efficiently degraded via the ERAD-L pathway.
###end p 38
###begin p 39
###xml 0 9 0 9 <label xmlns:xlink="http://www.w3.org/1999/xlink">FIGURE 6.</label>
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 9 73 9 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY is blocked in <italic>sec61-3</italic> cells at 17 &#176;C.</bold>
###xml 73 74 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 82 88 76 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 220 221 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 255 259 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. C</italic>
###xml 275 282 263 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 349 350 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 343 350 331 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 352 353 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 423 424 411 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 417 424 405 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 482 485 469 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHX</italic>
###xml 9 487 9 474 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><bold>ERAD of DPY* and OPY is blocked in <italic>sec61-3</italic> cells at 17 &#176;C.</bold><italic>A</italic>, as in <xref rid="fig5" ref-type="fig">Fig. 5</xref> except cells were incubated at 17 &#176;C after the addition of cold methionine, and samples were collected every 60 min for 4 h. <italic>B</italic>, quantification of data shown in <italic>A. C</italic>, wild type and <italic>sec62-1</italic> cells expressing DPY* or OPY* were analyzed as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>D</italic>, wild type cells expressing DPY* were analyzed as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref> with or without the addition of 10 &#956;g/ml cycloheximide (<italic>CHX</italic>).</p>
###xml 9 487 9 474 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><bold>ERAD of DPY* and OPY is blocked in <italic>sec61-3</italic> cells at 17 &#176;C.</bold><italic>A</italic>, as in <xref rid="fig5" ref-type="fig">Fig. 5</xref> except cells were incubated at 17 &#176;C after the addition of cold methionine, and samples were collected every 60 min for 4 h. <italic>B</italic>, quantification of data shown in <italic>A. C</italic>, wild type and <italic>sec62-1</italic> cells expressing DPY* or OPY* were analyzed as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>D</italic>, wild type cells expressing DPY* were analyzed as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref> with or without the addition of 10 &#956;g/ml cycloheximide (<italic>CHX</italic>).</p></caption>
###xml 487 487 474 474 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zbc0510857770006"/>
###xml 0 487 0 474 <fig xmlns:xlink="http://www.w3.org/1999/xlink" position="float" id="fig6"><label>FIGURE 6.</label><caption><p textid="40"><bold>ERAD of DPY* and OPY is blocked in <italic>sec61-3</italic> cells at 17 &#176;C.</bold><italic>A</italic>, as in <xref rid="fig5" ref-type="fig">Fig. 5</xref> except cells were incubated at 17 &#176;C after the addition of cold methionine, and samples were collected every 60 min for 4 h. <italic>B</italic>, quantification of data shown in <italic>A. C</italic>, wild type and <italic>sec62-1</italic> cells expressing DPY* or OPY* were analyzed as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>. <italic>D</italic>, wild type cells expressing DPY* were analyzed as described in <xref rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref> with or without the addition of 10 &#956;g/ml cycloheximide (<italic>CHX</italic>).</p></caption><graphic xlink:href="zbc0510857770006"/></fig>
FIGURE 6.ERAD of DPY* and OPY is blocked in sec61-3 cells at 17 degreesC.A, as in Fig. 5 except cells were incubated at 17 degreesC after the addition of cold methionine, and samples were collected every 60 min for 4 h. B, quantification of data shown in A. C, wild type and sec62-1 cells expressing DPY* or OPY* were analyzed as described in Fig. 3A. D, wild type cells expressing DPY* were analyzed as described in Fig. 3A with or without the addition of 10 mug/ml cycloheximide (CHX).
###end p 39
###begin p 40
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 0 64 0 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY is blocked in <italic>sec61-3</italic> cells at 17 &#176;C.</bold>
###xml 64 65 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 73 79 67 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 211 212 199 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 246 250 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. C</italic>
###xml 266 273 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 340 341 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 334 341 322 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 343 344 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 414 415 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 408 415 396 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 473 476 460 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHX</italic>
ERAD of DPY* and OPY is blocked in sec61-3 cells at 17 degreesC.A, as in Fig. 5 except cells were incubated at 17 degreesC after the addition of cold methionine, and samples were collected every 60 min for 4 h. B, quantification of data shown in A. C, wild type and sec62-1 cells expressing DPY* or OPY* were analyzed as described in Fig. 3A. D, wild type cells expressing DPY* were analyzed as described in Fig. 3A with or without the addition of 10 mug/ml cycloheximide (CHX).
###end p 40
###begin p 41
###xml 0 48 0 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERAD of DPY* and OPY* Requires Functional Sec61p</italic>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 352 359 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 572 579 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 663 669 651 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5</xref>
###xml 778 785 760 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
ERAD of DPY* and OPY* Requires Functional Sec61p-Next we sought to examine any requirement for Sec61p. We have earlier shown that DPY* and OPY* can be efficiently translocated into the ER in sec61-3 mutant cells at 30 degreesC. We therefore tested whether these translocated substrates were competent for ERAD under these same conditions. Wild type or sec61-3 mutant cells expressing either DPY* or OPY* were labeled at 30 degreesC, and samples taken at various time points during a chase performed at the same temperature. We found the half-life of both DPY* and OPY* in sec61-3 cells to be indistinguishable from that in wild type cells under these conditions (Fig. 5). These results demonstrate that DPY* and OPY* are available for ERAD after translocation at 30 degreesC in sec61-3 cells and that their degradation occurs with essentially wild type kinetics.
###end p 41
###begin p 42
###xml 220 227 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 369 370 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 375 376 357 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 361 376 343 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, <italic>A</italic> and <italic>B</italic></xref>
###xml 450 457 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
Next we tested for any effect on ERAD following inactivation of the Sec61p-dependent translocase at 17 degreesC. The ER was preloaded with ERAD-competent substrate by pulse labeling at 30 degreesC in either wild type or sec61-3 mutant cells. The cells were then shifted to 17 degreesC and chased in the presence of unlabeled methionine for the times indicated (Fig. 6, A and B). We observed a dramatic increase in the stability of both substrates in sec61-3 cells when compared with wild type controls. Thus functional Sec61p is required for the ER-associated degradation of both DPY* and OPY*.
###end p 42
###begin p 43
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 250 257 244 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
###xml 465 466 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 459 466 453 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 574 581 568 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 977 978 953 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 971 978 947 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 1314 1316 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref29">29</xref>
It remains formally possible that the severe translocation phenotype associated with sec61-3 at 17 degreesC might lead to an indirect effect on ERAD, perhaps by blocking the import of some essential factor. To rule this out we first examined ERAD in sec62-1 mutant cells in which post-translational translocation is specifically blocked but found no significant difference in the rate of degradation of either substrate when compared with wild type controls (Fig. 6C). Thus ERAD of these novel substrates does not require ongoing post-translational translocation. Of course sec61-3 cells are also deficient in co-translational translocation at 17 degreesC. We therefore tested the effects on our ERAD substrates of a complete block in all protein translocation by treating wild type cells with cycloheximide to inhibit protein synthesis. The cells were pulse-labeled at 30 degreesC and then chased at either 30 or 17 degreesC in the presence or absence of cycloheximide (Fig. 6D). We found no delay in the degradation of DPY* in the presence of drug. Because protein synthesis is not required for ERAD, it naturally follows that ongoing co-translational import of factors into the ER cannot be required. This is consistent with numerous studies in which ERAD has been observed in cells treated with cycloheximide (29).
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref7">7</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref26">26</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref30">30</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref31">31</xref>
###xml 410 414 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">der1</italic>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
###xml 647 648 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="ref2">2</xref>
A variety of studies implicate Der1p in ERAD, but its precise function remains unknown. It is clearly required for the degradation of a range of misfolded luminal proteins including CPY* (7). In contrast, the majority of membrane proteins tested appear to be degraded independently of Der1p (2, 26, 30, 31). One notable exception is the type I integral membrane protein, KWW, whose degradation is defective in der1 mutant cells (2). The misfolded lesion in KWW is located within its luminal domain leading to the suggestion that Der1p is required for the degradation of substrates with misfolded lumenal domains via a pathway now known as ERAD-L (2).
###end p 45
###begin p 46
###xml 344 351 344 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 839 846 839 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 1131 1138 1125 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec61-3</italic>
###xml 1497 1504 1479 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sec62-1</italic>
A number of studies have similarly implicated Sec61p in ERAD, but the role of Sec61p in the initial translocation of such substrates into the ER complicates the analysis of degradation kinetics. We have sought to temporally separate the known role of Sec61p in translocation from any subsequent role in ERAD by exploiting the properties of the sec61-3 mutant. We have created two new ERAD substrates, both of which are imported into the ER in an SRP-dependent manner. The first, DPY*, inserts into the ER membrane as a type II integral membrane protein, whereas the second, OPY*, is subject to signal peptide cleavage and is released into the ER lumen. Both DPY* and OPY* are substrates for Der1p-dependent ERAD and so, like CPY*, must be substrates for the ERAD-L pathway. As expected, both DPY* and OPY* were efficiently translocated in sec61-3 cells at the permissive temperature of 30 degreesC. These translocated forms of DPY* and OPY* were evidently available to the ERAD machinery because both were degraded with kinetics that were indistinguishable from those observed in wild type cells. This allowed us to load the ER in sec61-3 cells with ERAD-competent substrate and to then inactivate Sec61p by shifting cells to 17 degreesC. Our data demonstrate that the inactivation of sec61-3p at 17 degreesC results in a rapid and substantial block in the ERAD of both DPY* and OPY*. This cannot be explained by some indirect effect of a block in sec61-3-dependent protein import because neither sec62-1 nor cycloheximide treatment had any similar effect on ERAD.
###end p 46
###begin p 47
Our results demonstrate that functional Sec61p is essential for degradation of ERAD-L substrates. This finding supports a model in which Sec61p forms a bi-directional protein-conducting channel for the transport of polypeptide chains both into and out of the lumen of the endoplasmic reticulum. It will be interesting to determine whether or not different accessory factors might engage with Sec61p to determine the directionality of transport.
###end p 47
###begin title 48
Supplementary Material
###end title 48
###begin title 49
[Supplemental Data]
###end title 49
###begin p 50
###xml 164 169 <span type="species:ncbi:4932">yeast</span>
We thank Drs. Martin Pool and Barrie Wilkinson for helpful discussions and critical reading of the manuscript and Professors Steve Oliver and Mark Hochstrasser for yeast strains.
###end p 50
###begin p 51
The abbreviations used are: ER, endoplasmic reticulum; ERAD, ER-associated degradation; E2, ubiquitin carrier protein; E3, ubiquitin-protein isopeptide ligase; CPY, carboxypeptidase Y; SRP, signal recognition particle.
###end p 51

